Patients’ characteristics
| Characteristics . | n . | % . |
|---|---|---|
| Age, median (range), y | 75 (62-85) | — |
| Sex | ||
| Male | 22 | 67 |
| Female | 11 | 33 |
| WHO performance status | ||
| 0-1 | 23 | 70 |
| 2-3 | 10 | 30 |
| Diagnosis | ||
| De novo | 16 | 48 |
| Secondary MDS | 17 | 52 |
| Karyotype | ||
| Intermediate | 18 | 56 |
| Unfavorable | 13 | 39 |
| Not evaluable | 2 | 6 |
| Laboratory median data (range) | ||
| Hb, g/dL | 9.4 (7,6-12.3) | — |
| WBC, ×109/L | 3.05 (0.26-24.53) | — |
| PLT, ×109/L | 69 (6-260) | — |
| Blasts, % | 60 (16-96) | — |
| Characteristics . | n . | % . |
|---|---|---|
| Age, median (range), y | 75 (62-85) | — |
| Sex | ||
| Male | 22 | 67 |
| Female | 11 | 33 |
| WHO performance status | ||
| 0-1 | 23 | 70 |
| 2-3 | 10 | 30 |
| Diagnosis | ||
| De novo | 16 | 48 |
| Secondary MDS | 17 | 52 |
| Karyotype | ||
| Intermediate | 18 | 56 |
| Unfavorable | 13 | 39 |
| Not evaluable | 2 | 6 |
| Laboratory median data (range) | ||
| Hb, g/dL | 9.4 (7,6-12.3) | — |
| WBC, ×109/L | 3.05 (0.26-24.53) | — |
| PLT, ×109/L | 69 (6-260) | — |
| Blasts, % | 60 (16-96) | — |